Athenex, Inc. (ATNX) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector, currently trading at $0.20. It has a SharesGrow Score of 23/100, indicating a weak investment profile with 0 out of 7 criteria passed.
Financials: revenue is $103M, +3.8%/yr average growth. Net income is $99M (loss), growing at +-0%/yr. Net profit margin is -96.3% (negative). Gross margin is 26% (-5.2 pp trend).
Balance sheet: total debt is $42M with negative equity of -$7M — this means total liabilities exceed total assets. This is a warning sign that may indicate accumulated losses, aggressive share buybacks, heavy debt financing, or aggressive dividend payouts. Companies like McDonald's and Starbucks also carry negative equity due to buybacks and dividends, but investors should assess whether the business generates sufficient cash flow to service its debt and sustain payouts. Current ratio is 1.09 (adequate). Debt-to-assets is 20.8%. Total assets: $204M.
Analyst outlook: 5 / 10 analysts rate ATNX as buy (50%) — moderate consensus.
SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 45/100 (Partial), Past 0/100 (Fail), Health 25/100 (Fail), Moat 22/100 (Fail), Future 40/100 (Partial), Income 10/100 (Fail).
